Florida Cancer Specialists & Research Institute (FCS), one of the largest independent oncology practices in the United States, has announced the addition of Mina Aleksan, MD, a board-certified medical oncologist and hematologist, to its physician network. The appointment reinforces FCS’s strategic commitment to expanding specialist access across Florida at a time when demand for oncology services continues to rise alongside an aging state population. According to PR Newswire, the announcement underscores the institute’s ongoing effort to recruit dual-trained specialists capable of addressing both solid tumor malignancies and blood-based cancers under one practice umbrella. For context on how specialist-sector investment is reshaping healthcare delivery models across the country, The Fiscalist’s earlier coverage of seed round funding in adjacent healthcare-adjacent technology sectors illustrates the broader push toward expanding professional capacity in high-need disciplines.
Dr. Aleksan brings a clinical profile that spans both medical oncology and hematology, two disciplines that are increasingly managed together as treatment protocols for blood cancers and solid tumors converge. Her background equips her to treat patients across a broad spectrum of diagnoses, from lymphomas and leukemias to breast, lung, and gastrointestinal cancers. Florida, which is home to more than 4.5 million residents aged 65 and older — a demographic that accounts for a disproportionate share of new cancer diagnoses nationally — represents a particularly high-demand environment for such dual-trained clinicians. The American Cancer Society estimates that approximately 1.9 million new cancer cases are diagnosed across the United States each year, with oncology workforce capacity identified as a critical bottleneck in timely care delivery.
FCS Network Scale and Physician Recruitment Strategy
Florida Cancer Specialists & Research Institute operates one of the most expansive community-based oncology networks in the country, with more than 250 physicians practicing across over 100 locations throughout Florida. The organization has consistently pursued a growth model centered on recruiting fellowship-trained specialists who can deliver hospital-quality care in outpatient, community-based settings — a model that has drawn increasing attention from both patients and payers seeking to reduce care delivery costs without sacrificing clinical outcomes. Independent oncology practices like FCS have grown in strategic importance as hospital systems face mounting financial pressures and integrated health networks look to shift high-cost oncology care closer to patients’ homes.
The recruitment of Dr. Aleksan aligns with a broader industry trend in which large independent oncology groups are competing aggressively for dual-trained hematologist-oncologists, a subspecialty segment where physician supply has historically lagged behind clinical demand. Nationally, projections from workforce analysts suggest the oncology physician shortage could reach several thousand unfilled positions within the next decade, driven by both demographic demand growth and physician retirement rates in an older practitioner base. For FCS, adding specialists with hematology credentials provides a particular competitive advantage, as hematologic malignancies such as multiple myeloma and non-Hodgkin lymphoma represent some of the fastest-growing cancer diagnoses by volume in the United States.
Clinical Focus and Patient Access Implications
Dr. Aleksan’s dual specialization positions her to treat a patient population that often navigates complex diagnostic pathways before receiving definitive care. Blood cancers in particular are frequently identified through general practitioner referrals following abnormal laboratory panels, meaning patients benefit significantly from access to hematologists embedded within established oncology networks rather than standalone academic medical centers. By joining FCS, Dr. Aleksan enters a practice infrastructure that already supports clinical trial participation, multidisciplinary tumor boards, and coordinated pharmacy services — resources that independent practitioners operating outside such networks typically cannot offer at comparable scale.
FCS has historically emphasized its research capabilities alongside clinical care, positioning the institute as a destination for patients seeking access to investigational therapies within a community setting. The organization has participated in numerous National Cancer Institute-designated trials, and the integration of a hematologist-oncologist such as Dr. Aleksan is likely to expand its trial eligibility portfolio in blood cancer protocols. For patients in the communities she will serve, the practical implication is a meaningful reduction in referral lag time and travel burden — factors that epidemiological research consistently identifies as significant drivers of treatment delay and outcomes disparity in cancer care. The FCS announcement reflects both an institutional growth priority and a direct response to identifiable gaps in specialist access across the Florida healthcare landscape.